Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Objectives/Purpose:

To determine the safety and efficacy of a Vitamin K (Vit K) antagonist (warfarin) in treating Metachromatic Leukodystrophy (MLD).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cooper Health System
• Treatments: Warfarin

Criteria

Inclusion Criteria:

• Children with MLD, 1 to 10 years of age who have received and failed bone marrow transplantation or are excluded from the treatment due to delayed diagnosis or any other reasons.

Exclusion Criteria:

• Any Children with MLD who are eligible for and might receive ABMT.

• Any Children with MLD who suffer with a bleeding disorder, moderate to severe anemia or any other hematological disorders.

• Any contraindications systemic for anti-coagulation